SGTX Stock - Sigilon Therapeutics, Inc.
Unlock GoAI Insights for SGTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $12.94M | $9.60M | $13.37M | $14.15M | $4.64M |
| Gross Profit | $12.94M | $9.60M | $13.37M | $14.15M | $4.64M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-43,666,000 | $-75,636,000 | $-52,642,000 | $-44,123,000 | $-23,075,000 |
| Net Income | $-43,456,000 | $-78,236,000 | $-54,867,000 | $-44,569,000 | $-22,765,000 |
| Net Margin | -335.7% | -815.0% | -410.3% | -314.9% | -490.9% |
| EPS | $-1.34 | $-31.92 | $-22.67 | $-27.53 | $-18.85 |
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteEarnings History & Surprises
SGTXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 7, 2024 | — | — | — | — |
Q1 2024 | Mar 12, 2024 | — | — | — | — |
Q4 2023 | Nov 9, 2023 | $-3.28 | — | — | — |
Q3 2023 | Aug 7, 2023 | $-4.71 | $-2.89 | +38.6% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.23 | $-2.99 | -1200.0% | ✗ MISS |
Q1 2023 | Mar 14, 2023 | $0.38 | $-2.73 | -818.4% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-5.59 | $-3.51 | +37.2% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-5.98 | $-5.72 | +4.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-3.90 | $-5.59 | -43.3% | ✗ MISS |
Q1 2022 | Mar 14, 2022 | $-5.98 | $-7.15 | -19.6% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-8.97 | $-8.19 | +8.7% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-7.54 | $-8.45 | -12.1% | ✗ MISS |
Q2 2021 | May 10, 2021 | $-7.28 | $-7.80 | -7.1% | ✗ MISS |
Q1 2021 | Mar 18, 2021 | $1.37 | $1.15 | -16.1% | ✗ MISS |
Q3 2020 | Sep 30, 2020 | — | $-5.96 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-8.33 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-7.87 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-6.88 | — | — |
Latest News
Frequently Asked Questions about SGTX
What is SGTX's current stock price?
What is the analyst price target for SGTX?
What sector is Sigilon Therapeutics, Inc. in?
What is SGTX's market cap?
Does SGTX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SGTX for comparison